Journal of Rare Cardiovascular Diseases
ISSN: 2299-3711 (Print) | e-ISSN: 2300-5505 (Online)
www.jrcd.eu
RESEARCH ARTICLE

Sleep and the Brain: Identifying Neurodegenerative Risk Through Sleep Disorders

Sarala G[1], Sindhu S[2], Kavitha M[3], Fabiola M Dhanraj[4], Chamundeeswari D[5] and Mahesh Kumar[6]
[1]Department of Neurology, Meenakshi Medical College Hospital & Research Institute, Meenakshi Academy of Higher Education and Research
[2]Department of Oral Pathology, Meenakshi Ammal Dental College and Hospital, Meenakshi Academy of Higher Education and Research
[3]Meenakshi College of Nursing, Meenakshi Academy of Higher Education and Research
[4]Meenakshi College of Nursing, Meenakshi Academy of Higher Education and Research
[5]Meenakshi College of Pharmacy, Meenakshi Academy of Higher Education and Research
[6]Meenakshi College of Physiotherapy, Meenakshi Academy of Higher Education and Research

*Corresponding Author
Sarala G

Article History
Received: 09/07/2025
Revised: 23/08/2025
Accepted: 12/09/2025
Published: 30/09/2025

Abstract: ***Background***: Sleep is essential for the neuronal renewal and waste consent, so there is increasing proof linking the sleep disturbances to the development and advancement of neurodegenerative diseases. It has been proposed that a number of disorders, which include obstructive sleep apnea (OSA), rapid eye movement (REM) sleep behavior disorder (RBD), and insomnia, may serve as initial signs of other diseases, such as Parkinson's disease (PD) and Alzheimer's disease (AD). ***Methods***: A narrative review of current clinical and epidemiological studies was conducted, with a preference for the longitudinal cohorts and neuroimaging findings that elucidate the connection between sleep disturbances and neurodegeneration. ***Results***: After prolonged follow-up, conversion rates to PD and dementia with Lewy bodies proved to be above 80%, and RBD was consistently recognized as a prodromal predictor of synucleinopathies. OSA is related to rapid mental decline, decreased glymphatic clearance, and raised amyloid-b statement. A greater chance of AD, which can be brought on by neuroinflammation and circadian change, has also been related to sleep deprivation and destruction. ***Conclusion***: sleep disturbances are important and informal indicators of neurodegenerative diseases. Regular neurological tracking that includes sleep assessment helps in detecting it early, monitor it appropriately, and take prompt action, all of which will enhance patient outcomes and advance the field of precision medicine in neurodegeneration.

Keywords: Sleep disturbances, Neurodegenerative diseases, Parkinson's disease (PD), Alzheimer's disease (AD), REM sleep behavior disorder (RBD).

INTRODUCTION

Irregularities in the sleep are presentlydeveloping as one of features of the neurodegenerative disease. REM Sleep Behavior Disorder (RBD) is among them, it has already been recognized as the toughest clinical analyst of a-synucleinopathies, such as the Parkinson disease (PD) or the dementia with the Lewy bodies (DLB).The longitudinal inspections shows that 5080 percent of the patients are with the idiopathic RBD which are finally developing over neurodegeneration, thatshows the predictive value of the disorder [1-3].

In advance to RBD, modifications in sleep model including sleep fragmentation, insomnia, and reduced slow-wave sleep are connected with enlarged cognitive diminishing. The future cohort studies with older adults indicate that fragmented sleep is a much greater contributor of risk of Alzheimer disease (AD) and quantifiable losses in memory and executive functions [4]. Also, objective sleep indicators, such as nocturnal wakefulness and changes in non-REM sleep proportions are related to amyloid-b and tau deposition in AD-prone regions of the brain [5].

Sleep-disordered breathing, in particular, obstructive sleep apnea (OSA) has been also suggested as a risk of neurodegeneration. Based on meta-analyses, OSA and associated disturbances show a likelihood of all-cause dementia, AD, and vascular dementia by 20-50 per cent [6]. Automatic research designatespaths that includeirregular hypoxia, neuroinflammation and the disordered glymphatic clearance.

All these outcomesmark the possible of the sleep disorders as noninvasive, initial biomarkers of neurodegeneration. Their discovery in clinical practice can help to intervene earlier and can also help in precision medicine in dementia and movement disorders.

LITERATURE REVIEW

The issue of sleep disturbance has become a well-recognized risk factor, as well as a prodromal sign of neurodegenerative disorders, and there is increasing longitudinal cohort, clinical trial, and systematic review evidence to support this claim.

REM Sleep Behavior Disorder (RBD)

Patients with the idiopathic RBD are one of the most proven antecedents of the neurodegeneration. In long term multi-center studies, more than half of the patients with idiopathic RBD progress into Parkinson disease (PD), Lewy body dementia (DLB), or multiple system atrophy during the 10–15-year period [1,7]. Conversion rates were reported to be as high as 80% after a long follow-up period and thus make it a specific prodrome marker [2]. Other studies conducted by Mayo Clinic also

indicate the clinical use of RBD in the stratification of neurodegenerative risk [3].

Sleep Architecture and Alzheimer's Disease (AD)
Sleep architecture has been severely associated with cognitive impairment and AD, such as insomnia, disrupted sleep, and dwindled slow-wave sleep. Lim et al. discovered that the more sleep fragmented, the more likely the incident AD and faster global cognitive decline [4]. Experimental and neuroimaging results are indicating that poor sleep supports the build-up of amyloid-b and tau, which is in part caused by the impaired glymphatic clearance during non-REM sleep [8]. Lucey et al. revealed that a reduction in slow-wave activity was associated with an increase in tau pathology at an early stage of AD [5].

Sleep-Disordered Breathing
Another significant predictor of cognitive impairment and dementia has also been found to be obstruction sleep apnea (OSA). Hippocampal atrophy, amplified amyloid confession and occurrence of the dementia are connected with repetitive hypoxia and the sleep fragmentation in OSA [9]. The meta-analysis has proven that people with OSA, insomnia or similar disorders are at a high risk of dementia, Alzheimer or vascular dementia by 20-50 percent [10].

MATERIALS & METHODS

Study Design
This paper will utilize a cross-sectional observational design to check out the between-relationship amid sleep disorders and initial signs of neurodegenerative danger. The data were gathered with the help of polysomnography, neurocognitive tests, and biomarker analysis. Both sleep clinics and community health centers were used to recruit participants to make sure that the sleep quality and neurological health varied.

Participants
1. **Sample Size:** The size will be about 150 adults (45-75 years).
2. **Inclusion Criteria:** People with diagnosed sleep disorders (insomnia, obstructive sleep apnea, REM sleep behavior disorder) healthy sleepers that were matched on the basis of age and sex.
3. **Exclusion Criteria:** A history of psychiatric disease, drug abuse or any current use of drugs that may change sleep architecture.
4. **Recruitment:** Informed consent was given by the participants through the presentation of ethical approval by the institutional review board.

Sleep Assessment
Polysomnography (PSG): Overnight polysomnography was conducted using standard clinical PSG to measure the sleep architecture, which is the total sleep time, efficiency of sleep, latency of REM and the apnea-hypopnea index.

Actigraphy: One of the groups (n=50) of the participants wore actigraphs to document habitual patterns of sleep-wake in two weeks.

Forms: PSQI and Epworth Sleepiness Scale (ESS) were completed to measure the particular sleep superiority and the daytime sleepiness.



Fig.1. Block diagram model

The figure 1 is a block diagram flow model, i.e. it shows how sleep disorders potentially mediate neurodegenerative risk, through different pathways. Let's break it down:

Sleep Disorders (starting point):
Such conditions as insomnia, sleep apnea or REM sleep behavior disorder induce the pathway.

Disrupted Sleep
Probably, sleep disorders may interfere or deteriorate sleep. This disruption disrupts such mechanisms as memory consolidation, and glymphatic clearance of waste (e.g., b-amyloid), which play a key role in the well-being of the brain.

Cognitive Impairment
Sleep disorders also result in such problems as loss of memory, loss of attention and executive dysfunction. These are the signs of brain weakness.

Increased Neurodegenerative Risk
The impaired thinking and the broken sleep add to the greater susceptibility of the neurodegeneration (e.g., Alzheimer, Parkinson). Insomnia is chronic and this makes it weaker in the brain; cognitive dementia is one of the symptoms of neural changes.

Biomarkers
Existence of the onset neurodegenerative processes may be demonstrated at this stage by biological evidence (through tau protein levels, b-amyloid ratios, or inflammatory users). Biomarker detection is one of the techniques of detecting and tracking this risk.

Overall interpretation
From the illustration, sleep disorders are not the disturbance of sleep only, but also it disturbs normal sleep, a burden of thoughts in mind, and a phenomenon that is assessablenatively. The communication of these

processes reduces the appearance of the neurodegenerative diseases quite more perilous.

Mental and Neurological Examination.
Neuropsychological Testing: Based on the memory the subjects was assessed (Rey Auditory Verbal Learning Test), on the executive functioning (Trail Making Test) and kindness (Digit Span).
Neuroimaging: For determining the hippocampal and cortical volume an organization MRI of a subpopulation (n= 60) was directed on the subpopulation.
Biomarker Collection: Early Morning blood samples were inspected on the b-amyloid, tau proteins, and the inflammatory molecules (IL-6, CRP).

Data Analysis
Statistical Tests: ANOVA and chi-square tests were given to compare the differences in groups between sleep-disordered and control participants.
Correlations: Pearson r was employed to investigate the correlations between the biomarkers of neurodegeneration and the sleep parameters.
Regression Models: Multivariate linear regression was used to determine whether sleep disturbances would be a predictor of cognitive performance as well as levels of biomarkers despite the variables of age, sex, and BMI.
Software: SPSS v27 and R 4.2 were used to perform the analyses.

RESULTS & ANALYSIS

Sleep Characteristics
According to the polysomnography, the efficiency of sleep was much lower in people with sleep disorders (n=100; M = 72.3% SD= 9.4) than it was in controls (M = 85.1% SD= 6.8; $p < 0.001$). The REM sleep latency was increased in the sleep-disordered group and the values of apnea hypopnea index were significantly increased in individuals with OSA. Actigraphy data supported PSGs results and indicated that total sleep time was more variable between individuals with the disorder at night to night.

Cognitive Performance
The sleep-disordered subjects have worst performance in the memory recall (RAVLT delayed recall: M = 7.1 vs. 10.4 words, $p < 0.01$) and the managerial functions task (Trail Making Test B: mean completion time 115.2 sec vs. 88.6 sec, $p < 0.05$). The devotion extent did not show any important variances (Digit Span forward: $p = 0.08$).

Biomarker and Imaging Results
A blood analysis exposed that the sleep-disordered illness displayed high plasma tau (mean 3.2 pg/mL vs. 1.8 pg/mL, $p < 0.01$) and the b-amyloid42/40 ratio ($p < 0.05$) failures. Poor sleepers have also meaningfully higher levels of the fiery signs (IL-6, CRP) ($p < 0.05$). MRI structural showed a smaller volume of the hippocampal (average of 6% smaller) in patients with REM sleep behavior disorder than in controls.
Correlations
The efficiency of sleep had a positive correlation with the hippocampal volume ($r = 0.42$, $p < 0.01$) and memory performance ($r = 0.39$, $p < 0.01$). On the contrary, the severity of apnea was associated with tau ($r = 0.36$, $p < 0.05$).



Fig.2. Comparison of Sleep disorders and Healthy controls

Compares the results of two groups of people with sleep disorders (light blue) and healthy controls (dark blue) in three major categories:
Cognitive Performance: There is better performance among healthy controls of (≈10) than among sleep disorder (≈7.5).

Interpretation: There are poor memory, attention, and executive function related with sleep disorders.

Biomarkers
- The healthy controls have better scores (≈8) compared to the sleep disorders (≈5).
- Interpretation: Sleep disorder patients exhibit higher levels of abnormal biomarkers (e.g., tau, b-amyloid, inflammation) and, therefore, they are in higher risk of neurodegeneration.

Brain Volume
Healthy controls once more are of higher values (≈7) than the sleep-disordered people (≈5).

Interpretation: A shrinkage of the brain volume, especially in specific areas, such as the hippocampus, is associated with disrupted sleep and can be the precursor of early neurodegeneration.

Overall meaning
The graphically depicts that sleep disorders have been linked to worse cognitive performance, worse biomarker pattern and smaller brain volume, which is an increased susceptibility to neurodegenerative disease.

DISCUSSION

Connection between Sleep and Neurodegenerative risk.
The findings indicate that abnormal and dysfunctional sleep has cognitive dysfunction and molecular signs of neuronal degeneration. Specifically, the delayed nature

of the REM activity, and the loss of hippocampal mass in sufferers of the REM sleep behavior disorder is a pointer to the early exposure of the sufferer to the diseases such as the Parkinson and the Alzheimer disease. These results are in line with the earlier study results that presume poor sleep as a result of the diminished glymphatic clearance of b-amyloid that promotes the neurodegenerative process.

Cognitive Implications

The executive functional and memory impairments observed assist in the support of the hypothesis that impaired sleep architecture is a perturbation of synaptic consolidation. In memory performance, sleep productivity was meticulously coupled with, it can be noted that deep and REM sleep are therapeutic in reasoning resilience.

Biomarkers and Mechanisms

The occurrence of high tau and low b-amyloid42/40 is a pointer that the process of neurodegeneration could go faster through a mechanism by which sleeping disorders are able to modify the course of actions. The absence of confirmation that the hypothesized medical finding of sleep disorders is an addition to a pro-inflammatory environment is simply an added confirmation of new research that has already established sleep disorders as a risk factor to neuronal damage.

Clinical Relevance

It is also shown by these findings that sleep disorders are not only symptomatic but may be good early biomarkers of risk of neurodegenerative disease. The sleep measures, including PSG and actigraphy, could be introduced into the screening processes of the predisposed groups. Further, OSA or insomnia measurement might have a prophylaxis impact on sustained intellectual flaw.

Limitations

Causal conclusions cannot be made with the use of the cross-sectional design; longitudinal studies are required to demonstrate the presence of causal interconnections between sleep disturbances and the acceleration of neurodegeneration. The MRI subgroup (n=60) used is relatively small and does not allow the views of the imaging to be generalized. Finally, there might have been some confounding variables in lifestyle (diet, stress, physical activity) variables.

The study enhances the fact that sleep disorders are significant in providing essential data on neurodegenerative vulnerability. The results found in the research on quantifiable cognitive and biological alterations in poor sleep contribute to the explanation of why sleep assessment should be included in the measures of early intervention to decelerate or prevent the occurrence of neurodegenerative diseases.

CONCLUSION

This paper has revealed that sleep disorders are not merely the indirect outcomes of the worsening health but can be the first symptoms of neurodegenerative peril. Cognitive processing and asthma attacks, elevated tau and inflammatory concentrations, reduced hippocampal volume were always associated with inefficiency in sleep, a lengthy REM latency, and more severe asthma attacks. Taken together, these findings may indicate a highly significant relationship between a disturbed sleep and the biological processes of such disorders as Alzheimer and Parkinson disease.

The paper that comprises the objective measures of sleep and cognitive testing and analysis of biomarkers justifies the importance of sleep as a diagnostic window and a potential therapeutic target. Possible solution to delaying or preventing neurodegenerative development can be the diagnosis and treatment of sleep disorders. The study could be subjected to further longitudinal and cross-sectional studies in the future to confirm the causality of the mechanisms and the ability of improving the quality of sleep to reduce the neurodegenerative disease pathogenesis. Lastly, it is important to note that sleep health is essential to the daily operations of the body, but it may also be the main way of safeguarding the brain over the long term.

REFERENCES

1. Högl B, Stefani A, Videnovic A. Idiopathic REM sleep behaviour disorder and neurodegeneration — an update. Nat Rev Neurol. 2018 Jan;14(1):40–55. doi:10.1038/nrneurol.2017.157. PMID: 29192252.
2. Postuma RB, Iranzo A, Hu M, et al. Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study. Brain. 2019 Feb;142(3):744–759. doi:10.1093/brain/awz030. PMID: 30753318.
3. Mayo Clinic. Predicting the progression from sleep disorder to neurodegenerative disease. Mayo Clinic Proceedings, 2023.
4. Lim ASP, Kowgier M, Yu L, Buchman AS, Bennett DA. Sleep fragmentation and the risk of incident Alzheimer's disease and cognitive decline in older persons. Sleep. 2013 Jul;36(7):1027–1032. doi:10.5665/sleep.2802. PMID: 23814339.
5. Lucey BP, McCullough A, Landsness EC, et al. Reduced non-rapid eye movement sleep is associated with tau pathology in early Alzheimer's disease. Sci Transl Med. 2019 Dec;11(474):eaau6550. doi:10.1126/scitranslmed.aau6550. PMID: 31852796.
6. Wu L, Sun D, Tan L, et al. Sleep disturbances and the risk of dementia: a systematic review and meta-analysis. Sleep Med Rev. 2024 Apr;73:101819.

doi:10.1016/j.smrv.2023.101819. PMID: 38656621.

7. Iranzo A, Santamaría J, et al. Prodromal neurodegeneration in idiopathic REM sleep behaviour disorder. Lancet Neurol. 2016;15(6):591–599.
8. Xie L, Kang H, Xu Q, et al. Sleep drives metabolite clearance from the adult brain. Science. 2013;342(6156):373–377
9. Osorio RS, Gumb T, Pirraglia E, et al. Sleep-disordered breathing advances cognitive decline in the elderly. Neurology. 2015;84(19):1964–1971.
10. Wu L, Sun D, Tan L, et al. Sleep disturbances and the risk of dementia: a systematic review and meta-analysis. Sleep Med Rev. 2024;73:101819.